A Novel 3D Printed Model of Infected Human Hair Follicles to Demonstrate Targeted Delivery of Nanoantibiotics
Source abstract
Abstract
High Resolution Image Download MS PowerPoint Slide Hair follicle-penetrating nanoparticles offer a promising avenue for targeted antibiotic delivery, especially in challenging infections like acne inversa or folliculitis decalvans. However, demonstrating their efficacy with existing preclinical models remains difficult. This study presents an innovative approach using a 3D in vitro organ culture system with human hair follicles to investigate the hypothesis that antibiotic nanocarriers may reach bacteria within the follicular cleft more effectively than free drugs. Living human hair follicles were transplanted into a collagen matrix within a 3D printed polymer scaffold to replicate the follicle’s microenvironment. Hair growth kinetics over 7 days resembled those of simple floating cultures. In the 3D model, fluorescent nanoparticles exhibited some penetration into the follicle, not observed in floating cultures. Staphylococcus aureus bacteria displayed similar distribution profiles postinfection of follicles. While rifampicin-loaded lipid nanocapsules were as effective as free rifampicin in floating cultures, only nanoencapsulated rifampicin achieved the same reduction of CFU/mL in the 3D model. This underscores the hair follicle microenvironment’s critical role in limiting conventional antibiotic treatment efficacy. By mimicking this microenvironment, the 3D model demonstrates the advantage of topically administered nanocarriers for targeted antibiotic therapy against follicular infections.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Hair Growth and Disorders · Dermatology and Skin Diseases · Advancements in Transdermal Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Drug Delivery, Helmholtz Center for Infection Research, Helmholtz-Institute for Pharmaceutical Research Saarland, Campus E8 1, Saarbrücken 66123, Germany
Saarland University, Saarbrücken 66123, Germany
Specialist in Plastic and Aesthetic Surgery, Saarbrücken 66111, Germany
Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Troy, New York 12180, United States
Clinic for Dermatology, University Clinic Homburg, Kirrberger Str., Homburg 66424, Germany
References (44)
Show source-provided references
1. 10.1159/00009311910.1159/000093119 ↗
2. 10.1016/j.ajps.2022.04.00310.1016/j.ajps.2022.04.003 ↗
3. 10.1016/j.jconrel.2020.09.05310.1016/j.jconrel.2020.09.053 ↗
4. 10.1016/j.addr.2020.05.01110.1016/j.addr.2020.05.011 ↗
5. 10.1016/j.ejpb.2006.10.01910.1016/j.ejpb.2006.10.019 ↗
6. 10.1016/j.jconrel.2014.01.01810.1016/j.jconrel.2014.01.018 ↗
7. 10.1111/srt.1300810.1111/srt.13008 ↗
8. 10.1016/j.jid.2019.05.02810.1016/j.jid.2019.05.028 ↗
9. 10.1242/jcs.97.3.46310.1242/jcs.97.3.463 ↗
10. 10.1111/exd.1283610.1111/exd.12836 ↗
11. 10.1038/s41467-018-07579-y10.1038/s41467-018-07579-y ↗
12. 10.1111/j.1529-8019.2008.00204.x10.1111/j.1529-8019.2008.00204.x ↗
13. 10.1111/jdv.1707910.1111/jdv.17079 ↗
14. Vinkel C. · J. Clin. aesthetic Dermatol. · 2018 · 11 · 17
15. 10.2340/00015555-259110.2340/00015555-2591 ↗
16. 10.2147/CCID.S40245310.2147/CCID.S402453 ↗
17. 10.1111/jdv.1299310.1111/jdv.12993 ↗
18. 10.4103/0974-7753.6690810.4103/0974-7753.66908 ↗
19. 10.1159/00050732310.1159/000507323 ↗
20. 10.1111/j.1468-3083.2012.04591.x10.1111/j.1468-3083.2012.04591.x ↗
21. 10.4103/ijt.ijt_98_2010.4103/ijt.ijt_98_20 ↗
22. 10.1016/j.colsurfb.2020.11144810.1016/j.colsurfb.2020.111448 ↗
23. 10.21577/0103-5053.2020001810.21577/0103-5053.20200018 ↗
24. 10.1016/j.jconrel.2013.06.01410.1016/j.jconrel.2013.06.014 ↗
25. 10.1021/acsbiomaterials.7b0007210.1021/acsbiomaterials.7b00072 ↗
26. 10.1016/S0733-8635(05)70090-510.1016/S0733-8635(05)70090-5 ↗
27. 10.1096/fj.12-21815610.1096/fj.12-218156 ↗
28. 10.1111/j.1600-0625.2009.00939.x10.1111/j.1600-0625.2009.00939.x ↗
29. 10.1016/j.ejpb.2020.11.01810.1016/j.ejpb.2020.11.018 ↗
30. 10.1016/j.ejpb.2016.10.00510.1016/j.ejpb.2016.10.005 ↗
31. 10.1166/jbn.2010.114510.1166/jbn.2010.1145 ↗
32. 10.4103/0974-2077.6901510.4103/0974-2077.69015 ↗
33. 10.1111/apm.1210310.1111/apm.12103 ↗
34. 10.1016/j.jhin.2010.07.01110.1016/j.jhin.2010.07.011 ↗
35. 10.1016/j.jid.2021.02.00910.1016/j.jid.2021.02.009 ↗
36. 10.1007/s00403-010-1030-y10.1007/s00403-010-1030-y ↗
37. 10.1038/s41536-020-0095-210.1038/s41536-020-0095-2 ↗
38. 10.1016/j.ejps.2015.07.01810.1016/j.ejps.2015.07.018 ↗
39. 10.1016/j.ijpharm.2022.12226410.1016/j.ijpharm.2022.122264 ↗
40. 10.1016/j.ejpb.2016.07.01610.1016/j.ejpb.2016.07.016 ↗
41. 10.1038/s41598-019-56760-w10.1038/s41598-019-56760-w ↗
42. 10.3389/fmicb.2020.0026510.3389/fmicb.2020.00265 ↗
43. 10.3390/pharmaceutics1402031910.3390/pharmaceutics14020319 ↗
44. 10.1016/j.actbio.2023.04.03410.1016/j.actbio.2023.04.034 ↗